{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The identification of a novel mutation (E46K) in one of the KTKEGV-type repeats in the amino-terminal region of α-synuclein suggests that this region and, more specifically, Glu residues in the repeats may be important in regulating the ability of α-synuclein to polymerize into amyloid fibrils... aberrant α-synuclein polymerization resulting in the formation of pathological inclusions can lead to disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as aberrant polymerization of α-synuclein into amyloid fibrils, leading to pathological inclusions associated with neurodegenerative diseases like Parkinson's disease (PD) and dementia with Lewy bodies (DLB)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The polymerization of α-synuclein was studied using filament assembly and centrifugal sedimentation, K114 fluorometry, CD spectrometry, ATR-FTIR spectroscopy, and negative staining electron microscopy (EM) to assess fibril formation and ultrastructure.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (e.g., sedimentation, fluorometry, spectrometry, and EM) are well-established in the field for studying protein polymerization and amyloid fibril formation, directly reflecting the disease mechanism of α-synuclein aggregation in synucleinopathies.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type (WT) α-synuclein was used as a control for comparison with mutant proteins. Experiments were conducted with multiple replicates as indicated by 'n = 6 for all data sets' in the results section.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type α-synuclein as a normal/negative control. Although an abnormal/positive control (e.g., a known loss-of-function mutant) is not explicitly described beyond A53T (which is also under study), the use of multiple replicates (n=6) is explicitly stated, satisfying the replicate condition and partially meeting control requirements.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The A53T mutation, a known pathogenic variant associated with autosomal dominant Parkinson's disease, was used as a comparator in the assays alongside E46K and other synthetic mutants.",
          "judgment": "Yes",
          "reasoning": "The A53T mutation serves as a known pathogenic variant control in the study, meeting the requirement for variant controls as it is well-documented in the literature as causal for PD.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative data from sedimentation assays and K114 fluorometry are provided with replicate information (n=6), but no specific statistical tests, p-values, or OddsPath calculations are reported for E46K relative to controls.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data and replicate numbers, there are no explicit statistical analyses or OddsPath calculations to quantify the likelihood of pathogenicity for E46K based on functional data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Variant Controls",
          "extracted_paper_info": "The study includes A53T as a known pathogenic variant control, but no additional benign or pathogenic variant controls beyond the mutants under investigation (E46K, E46A, E83A, E83K) are mentioned.",
          "judgment": "10 or less",
          "reasoning": "Only one known pathogenic variant control (A53T) is explicitly used in the study, which is less than the threshold of 11 total benign/pathogenic controls required for moderate evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA E46K supports pathogenicity at a supporting level (PS3_supporting) due to increased fibril formation compared to wild-type as demonstrated by multiple assays. However, the lack of extensive statistical analysis and limited number of variant controls (only A53T) restricts the strength to supporting rather than moderate or very strong."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "α-Synuclein was directly implicated in neurodegenerative disease when the mutation A53T was identified in a large Italian family (Contursi) and three small Greek families with autosomal dominant Parkinson's disease (PD)... aberrant α-synuclein polymerization resulting in the formation of pathological inclusions can lead to disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as aberrant polymerization of α-synuclein into amyloid fibrils, leading to pathological inclusions associated with PD, directly linked to the A53T mutation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The polymerization of α-synuclein was studied using filament assembly and centrifugal sedimentation, K114 fluorometry, CD spectrometry, ATR-FTIR spectroscopy, and negative staining electron microscopy (EM) to assess fibril formation and ultrastructure.",
          "judgment": "Yes",
          "reasoning": "The assays used (sedimentation, fluorometry, spectrometry, EM) are standard in the field for studying protein polymerization and amyloid fibril formation, directly relevant to the disease mechanism of α-synuclein aggregation in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type (WT) α-synuclein was used as a control for comparison with mutant proteins. Experiments were conducted with multiple replicates as indicated by 'n = 6 for all data sets' in the results section.",
          "judgment": "Yes",
          "reasoning": "Wild-type α-synuclein serves as a normal/negative control, and the paper explicitly states multiple replicates (n=6). While an abnormal/positive control beyond the mutants under study is not fully distinct, the replicate condition is met, partially satisfying control requirements.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares A53T with other mutants (E46K, E46A, E83A, E83K) and wild-type, but no additional known pathogenic or benign variant controls beyond A53T itself are explicitly used.",
          "judgment": "No",
          "reasoning": "A53T is the variant under study and cannot serve as its own control. No other known pathogenic or benign variants are used as controls in the assays beyond the mutants being tested.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A53T supports pathogenicity at a supporting level (PS3_supporting) due to a greater increase in fibril formation compared to wild-type and E46K as shown by multiple assays. However, the absence of additional variant controls beyond the mutants under study limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "A",
          "position": "46"
        },
        "variant_string_id": "SNCA E46A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates synthetic mutations like E46A to understand the role of Glu residues in modulating α-synuclein polymerization into amyloid fibrils, a mechanism linked to neurodegenerative diseases.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as aberrant α-synuclein polymerization into amyloid fibrils, relevant to the synthetic mutation E46A as it is studied in the context of fibrillogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include filament assembly and centrifugal sedimentation, K114 fluorometry, CD spectrometry, ATR-FTIR spectroscopy, and EM to study fibril formation.",
          "judgment": "Yes",
          "reasoning": "The assays are standard for studying protein aggregation and fibril formation, directly applicable to the disease mechanism of α-synuclein polymerization.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type (WT) α-synuclein was used as a control, and experiments were conducted with replicates (n=6).",
          "judgment": "Yes",
          "reasoning": "Wild-type serves as a normal control, and replicates are explicitly mentioned (n=6), partially meeting control and fully meeting replicate requirements.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "A53T, a known pathogenic variant, was used as a comparator in the assays alongside E46A and other mutants.",
          "judgment": "Yes",
          "reasoning": "A53T serves as a known pathogenic variant control, meeting the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative data from sedimentation and K114 fluorometry are provided with replicates (n=6), but no statistical tests or OddsPath calculations are reported for E46A.",
          "judgment": "No",
          "reasoning": "No explicit statistical analyses or OddsPath calculations are provided to quantify pathogenicity likelihood for E46A.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Variant Controls",
          "extracted_paper_info": "Only A53T is used as a known pathogenic variant control, with no additional benign or pathogenic controls mentioned.",
          "judgment": "10 or less",
          "reasoning": "With only one known pathogenic variant control (A53T), the total number of controls is below the threshold of 11 required for moderate evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA E46A supports pathogenicity at a supporting level (PS3_supporting) due to increased polymerization propensity, though with distinct ultrastructure. The limited number of variant controls and lack of statistical analysis restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "A",
          "position": "83"
        },
        "variant_string_id": "SNCA E83A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations at Glu 83 were studied to assess their role in α-synuclein polymerization, linked to pathological inclusions in neurodegenerative diseases.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism of aberrant α-synuclein polymerization into amyloid fibrils is clearly defined and relevant to the synthetic mutation E83A."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include sedimentation, K114 fluorometry, CD spectrometry, ATR-FTIR, and EM to study fibril formation.",
          "judgment": "Yes",
          "reasoning": "These assays are standard for assessing protein aggregation, directly applicable to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type α-synuclein was used as a control, with replicates (n=6) explicitly mentioned.",
          "judgment": "Yes",
          "reasoning": "Wild-type serves as a normal control, and replicates are documented, partially meeting control and fully meeting replicate requirements.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "A53T, a known pathogenic variant, was used as a comparator in the assays.",
          "judgment": "Yes",
          "reasoning": "A53T serves as a known pathogenic variant control, meeting the requirement.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative data are provided with replicates (n=6), but no statistical tests or OddsPath calculations are reported for E83A.",
          "judgment": "No",
          "reasoning": "Lack of statistical analysis or OddsPath calculation for E83A limits quantitative assessment of pathogenicity.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Variant Controls",
          "extracted_paper_info": "Only A53T is used as a known pathogenic variant control.",
          "judgment": "10 or less",
          "reasoning": "With only one control variant (A53T), the total is below the threshold of 11 for moderate evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA E83A supports pathogenicity at a supporting level (PS3_supporting) due to increased polymerization, though with reduced amyloid characteristics. Limited variant controls and no statistical analysis restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "83"
        },
        "variant_string_id": "SNCA E83K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations at Glu 83 were studied to assess their role in α-synuclein polymerization, linked to pathological inclusions in neurodegenerative diseases.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism of aberrant α-synuclein polymerization into amyloid fibrils is defined and relevant to E83K."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include sedimentation, K114 fluorometry, CD spectrometry, ATR-FTIR, and EM.",
          "judgment": "Yes",
          "reasoning": "These assays are appropriate for studying protein aggregation, relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type α-synuclein was used as a control, with replicates (n=6).",
          "judgment": "Yes",
          "reasoning": "Wild-type control and replicates are present, partially meeting control and fully meeting replicate requirements.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "A53T, a known pathogenic variant, was used as a comparator.",
          "judgment": "Yes",
          "reasoning": "A53T serves as a known pathogenic control, meeting the requirement.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative data with replicates (n=6) are provided, but no statistical tests or OddsPath calculations for E83K.",
          "judgment": "No",
          "reasoning": "No statistical analysis or OddsPath calculation limits quantitative pathogenicity assessment for E83K.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Variant Controls",
          "extracted_paper_info": "Only A53T is used as a known pathogenic variant control.",
          "judgment": "10 or less",
          "reasoning": "With only one control variant, the total is below the threshold of 11.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA E83K supports pathogenicity at a supporting level (PS3_supporting) due to increased polymerization, though with altered amyloid properties. Limited variant controls and lack of statistical analysis restrict the strength to supporting."
    }
  ]
}